BREAKING: AtaiBeckley Shareholders Vote to Accept Eli Lilly Merger During a special meeting that just concluded, $ATAI shareholders passed a proposal to accept a merger offer from $LLY.

If MDMA could help someone with PTSD from war, rape or other horrific experiences, then it would be wrong to withhold such a drug from them

JUST IN: Lab monkey prices in China have reportedly surged to roughly $26,000 each, as the biotech boom overwhelms supply.

Peptides are a revolutionary new healthcare platform Incumbents are intelligent enough to understand it, but they have the short term incentives to pretend it doesn’t exist It’s deflationary to a system that manages symptoms instead of healing at the root, which is what peptides do Further, most of the value will not accrue to the peptides themselves, but to the data layer that is able to personalize peptides for anyone at a marginal cost to maximize healthcare outcomes The above is the basis for longevity as a service, which will be far more valuable than any subscription service we’ve see to date. It’ll make Amazon look irrelevant and consumers will do everything in their power to continuously buy into longevity upgrades for themselves and their loved ones

Rapamycin trial design has been hard to figure out. Any first-in-human trial means making assumptions about what will work before you have data to back your decisions. But multiple trials are now running exploring various designs and endpoints, four of which we funded through Impetus Grants @impetusgrants. Three are testing clinical outcomes in specific populations. VIBRANT-I at Columbia is testing weekly low-dose rapamycin in women in their thirties to slow ovarian aging, showing early separation in ovarian reserve, with VIBRANT-II already in setup. RAPID at the University of Washington is running it in adults over fifty with periodontal disease, with aging biomarkers and microbiome sequencing built into the protocol. ERAP at the Karolinska tested it in fourteen early-stage Alzheimer's patients over six months, with primary imaging endpoints holding steady or improving in exploratory regions versus natural history progression. The fourth is asking a more foundational question. RAP-PROTECT at Wisconsin recruited fifty people already taking rapamycin off-label, drew blood at home, and ran metabolomic and lipidomic profiling to see which aging biomarkers actually respond to mTORC1 inhibition. Between them, they are doing the work of figuring out how to run a good trial for rapamycin as a longevity drug. We hope that our infrastructure can now finally to the science.